News | News By Subject | News by Disease News By Date | Search News

Liver or Gallbladder Disorder (misc) News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
SoCal's Regulus (RGLS) Sinks After AstraZeneca PLC (AZN) Bails on Lead NASH Drug     6/13/2017
Backed By Two Drug Powerhouses, GenSight Alum Launches New Biotech With $40 Million     5/4/2017
Gilead (GILD)'s $600 Million NASH Deal Finally Bears Fruit     4/26/2017
Look Out, Another Biotech Joins San Diego With $40 Million and Will Take on NASH     4/13/2017
Why Intercept Pharma (ICPT) Stock Jumped Nearly 10% On Friday After Providing Phase III Update     2/13/2017
Here's a Look at Allergan (AGN)'s Opportunity in NASH     1/16/2017
Bristol-Myers Squibb (BMY) Slams Down $100 Million to Make a Play Into NASH     11/14/2016
Gilead (GILD) Looking Even Weaker on the R&D Front as It Racks Up Some More Clinical Failures in Q3 Report     11/2/2016
The $40 Billion NASH Market and the 3 Biotechs That Stand to Profit From it     11/2/2016
Massachusetts's Alnylam (ALNY) Falls After Stopping Development of RNAi Liver Disease Candidate ALN-AAT     10/3/2016
Galectin (GALT) Stock Craters After Phase IIa NASH Failure     9/28/2016
This Biotech Has the Upper Hand Over Allergan (AGN) and Gilead (GILD) in the Heated Nash Battle     9/23/2016
Allergan (AGN)'s NASH Spree Continues With $50 Million+ Buyout of San Diego's Akarna Therapeutics     9/21/2016
Gilead (GILD) to Release Data on 9 Clinical Trials Before End of the Year     9/16/2016
Tobira (TBRA) Stock Loses More Than Half Its Value After Phase IIb Trial Miss     7/25/2016

News from Around the Web
3 Major Variables That Could Derail The Dash To NASH     5/1/2017
Why Gilead (GILD) Should Pay Close Attention And Maybe Even Fear Allergan (AGN)'s NASH Program     4/25/2017
Liver Disease In Children Linked To Fructose Intake, Journal of Hepatology Reveals     2/15/2017
Allergan (AGN) R&D Chief Reveals 6 Drugs That Could be Potential Blockbusters     2/14/2017
4 Small Biotechs That Could Give Gilead (GILD), Merck & Co. (MRK) Pfizer (PFE) Some Competition With NASH     10/7/2016
Citrus Fruits Could Help Prevent Obesity, Universidade Estadual Paulista Study     8/22/2016
Simple Blood Test Developed To Screen For Life-Threatening Liver Disease, Baylor College of Medicine Study     8/11/2016
A Colony Of Fat Mice Hidden In A Norfolk Lab Could Hold The Key For Liver Disease, Eastern Virginia Medical School Study     7/26/2016
Salem Nonprofit, Design That Matters, Creates Device To Treat Jaundice In Developing World     7/21/2016
Even Light Drinkers Should Watch For Fatty Liver Disease, Kumamoto University Study     5/25/2016
How Fasting Helps Fight Fatty Liver Disease, Helmholtz Zentrum Munchen Study     5/10/2016
How Waist Size Can Predict Liver Disease Risk, University Of Milan Study     4/18/2016
Why It Feels So Good To Scratch An Itch, Published In Proceedings Of The Entomological Society Of Washington     2/29/2016
Biotech Startup Pandorum Technologies Creates India’s First 3D Printed Artificial Human Liver Tissue     12/29/2015
Could Image Mapping Offer Way To Do Noninvasive Liver Biopsies?     10/20/2015

Press Releases
CymaBay Therapeutics Announces Positive Interim Results From Its Ongoing Low-Dose Phase II Study Of Seladelpar In Patients With Primary Biliary Cholangitis     7/17/2017
Spark Therapeutics (ONCE)’ Biologics License Application For Investigational Voretigene Neparvovec Accepted For Filing By FDA     7/17/2017
Immuron Release: NASH Phase II Interim Analysis Reveals Improvement In Liver Enzymes (AST And ALT) With Good Safety And Tolerability     7/10/2017
FDA Grants Conatus Pharma Orphan Drug Designation For IDN-7314 For The Treatment Of PSC     6/26/2017
Sirnaomics Advances Leading siRNA Therapeutic Candidate, STP705, For Treatment Of Liver Fibrosis     6/15/2017
uniQure (QURE) Publishes Data Further Demonstrating Favorable Immunogenicity Profile And Broad Utilization Of AAV5-Based Gene Therapies     6/15/2017
Galectin (GALT) Announces Important Milestones Towards Completion Of NASH CX Trial     6/13/2017
Intercept Pharma (ICPT) Announces New Data Analysis From FLINT Trial Of OCA In NASH Patients With Type 2 Diabetes     6/12/2017
ProSciento And OWL Metabolomics Form Strategic Collaboration Focused On Accelerating NAFLD/NASH Clinical Trial Recruitment     6/7/2017
Viking Therapeutics (VKTX) Announces Promising Top Line Results From In Vivo Study Of VK2809 In Non-Alcoholic Steatohepatitis (NASH)     6/6/2017
Lung Therapeutics Raises $14.3 Million Series B Financing To Treat Unmet Needs In Lung Disease And Fibrosis     6/6/2017
Vital Therapies (VTL) Announces Characteristics Of Early Subjects In VTL-308 Pivotal Study Of ELAD System In Severe Alcoholic Hepatitis     6/5/2017
Bird Rock Bio Completes Single Ascending Dose Human Clinical Trial For Namacizumab; Generates Safety, Tolerability, And Pharmacokinetics Data; Prepares To Initiate Study In Non-Alcoholic Fatty Liver Disease Patients     6/5/2017
New Preclinical Data On Can-Fite BioPharma (CFBI)'s Namodenoson To Be Presented At 1st International Conference On Fatty Liver In Seville, Spain On June 2, 2017     6/1/2017
Ocera Therapeutics (OCRX) Initiates Phase IIa Study With Oral OCR-002 In Patients With Cirrhosis     6/1/2017

//-->